BioSpace News Archive

Gritstone bio, Inc. announced that the Compensation Committee of the company’s Board of Directors has granted five employees nonqualified stock options to purchase an aggregate of 82,200 shares of its common stock, as an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 41st Annual Growth Stock Conference which takes place June 1-3, 2021. Ron Rocca, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, June 2 at 11:20 AM EDT.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, will present at the Jefferies Virtual Healthcare Conference, from 3:30-3:55pm ET on Thursday, June 3, 2021. Opiant will also host 1x1 investor meetings during the conference.

Sharps Compliance Corp., a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, announced that Jack Holmes has resigned from the Company’s Board of Directors, effective May 21, 2021, to focus on other business commitments.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus and Aziz Mottiwala, Chief Commercial Officer of Tarsus will present an overview of the company at the Jefferies Virtual Healthcare Conference

Zymergen Inc. (“Zymergen”), one of the world’s leading biofacturing companies, today reported preliminary financial results for the first quarter ended March 31, 2021.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 22,258,066 shares of its common stock,

- Treprostinil is indicated for Pulmonary Arterial Hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise¹ - PAH is rare, progressive disease with no cure that primarily affects women, often in their 30s to 60s, and may result in heart failure and shortened life expectancy² - Sandoz generic Treprostinil Injection now available for both subcutaneous and intravenous administration, providing PAH patients two options at lower cost

Dalrada Corporation (OTCQB: DFCO , “Dalrada”) is pleased to announce to its shareholders and the public that Dr. David Bacon, was appointed to Dalrada’s Board of Directors.

Horizon Therapeutics plc announced that the Company will participate in the following upcoming conferences